Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A study to determine how BI 907828 (Brigimadlin) is taken up in the tumor (Phase 0) and to determine the highest dose of BI 907828 (Brigimad… Ended

2023-506409-20-00 Glioblastoma 3 2023-11-24
AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEW… Ended

2023-504545-31-00 colorectal cancer 1 2023-11-23
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended

2023-503418-63-00 Head and Neck Squamous Cell Carcinoma 4 2023-11-23
Part C of A Phase 1b/2a Study of LY2880070 in Patients with Advanced or Metastatic Cancer Ended

2023-503459-91-00 Advanced or Metastatic Cancer 4 2023-11-21
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer Ended

2023-505938-98-00 Ovarian Cancer 4 2023-11-17
Study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer Ended

2022-502440-12-00 metastatic clear cell renal cancer with progressive dis 9 2023-11-16
MK-1084 Single and Multiple Dose Healthy Participant Study Ended

2023-507529-41-00 Solid tumor cancer and lung cancer 3 2023-11-07
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer Ended

2022-503108-26-00 Solid Tumor 7 2023-11-06
A 3-Part Phase 1 Study to Investigate the Absolute Oral Bioavailability and Absorption, Metabolism, and Excretion of 14C-Unesbulin in Patien… Ended

2022-502118-10-00 Solid tumors 3 2023-10-27
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Ended

2022-502476-23-00 Treatment of immunotherapy-naive patients with previous 4 2023-10-25
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Metastatic Breast Cancer HR+, HER2- 4 2023-10-19
A Study of NB003 in Patients With Advanced Malignancies Ended

2022-502401-15-00 Gastrointestinal stromal tumor 7 2023-10-19
A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hemato… Ended

2022-502672-23-00 Richter's Syndrome 3 2023-10-18
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended

2023-503830-27-00 Large B-Cell Lymphoma (LBCL) 4 2023-10-17
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer Ended

2022-502125-17-00 Advanced solid tumors 1 2023-10-16
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First Line or Second-Line Therapy in A… Ended

2023-504940-32-00 Gastric cancer 4 2023-10-13
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended

2023-503903-27-00 metastatic or locally advanced Hormone Receptor positiv 4 2023-10-11
A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE… Ended

2023-503251-10-00 Metastatic Breast Cancer or Advanced Non-Small Cell Lun 4 2023-10-10
A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep… Ended

2023-503846-30-00 Breast Cancer 9 2023-10-10
A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid T… Ended

2023-503449-79-00 Advanced or Metastatic Solid Tumours 3 2023-10-10
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patient… Ended

2024-511007-41-00 Untreated advanced or metastatic non-squamous non-small 9 2023-10-03
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refr… Ended

2022-502057-33-00 Relapsed/refractory multiple myeloma 7 2023-10-02
Study of GS-4528 for Adults With Solid Tumors Ended

2022-502070-16-00 Solid Tumors 1 2023-10-02
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended

2022-501927-25-00 Large B-Cell Lymphoma (LBCL) 4 2023-09-29